Tegaserod maleate

Tegaserod Maleate is a medication primarily used in the treatment of Irritable Bowel Syndrome (IBS) and Chronic Idiopathic Constipation (CIC). It is a selective 5-HT4 receptor agonist that acts on the cells in the gastrointestinal tract and has prokinetic properties.

History

Tegaserod Maleate was first approved by the Food and Drug Administration (FDA) in 2002 for the treatment of IBS in women and was marketed under the brand name Zelnorm by Novartis. However, it was withdrawn from the U.S. market in 2007 due to concerns about cardiovascular risks. In 2019, the FDA approved its reintroduction for women under 65 who do not have a history of cardiovascular disease.

Mechanism of Action

Tegaserod Maleate works by stimulating the 5-HT4 receptors in the gastrointestinal tract. This leads to increased release of acetylcholine, which in turn stimulates the smooth muscle in the gastrointestinal tract, promoting motility and the release of fluid. This helps to alleviate the symptoms of IBS and CIC.

Side Effects

Common side effects of Tegaserod Maleate include headache, abdominal pain, and diarrhea. Serious side effects can include severe chest pain, heart attack, stroke, and ischemic colitis.

Contraindications

Tegaserod Maleate is contraindicated in patients with a history of heart attack, stroke, angina, or any other form of cardiovascular disease. It is also contraindicated in patients with severe kidney disease or moderate to severe liver disease.

See Also

• Irritable Bowel Syndrome
• Chronic Idiopathic Constipation
• 5-HT4 receptor
• Food and Drug Administration
• Novartis